Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Filings indexed 1,660 across all filing types
Latest filing 2024-05-16 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Please find attached issuance of letter of confirmation against duplicate share certificate
Regulatory Filings
2024-05-16 English
Please find attached intimation of loss of share certificate
Regulatory Filings
2024-05-16 English
Board Meeting — MOREPEN LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 21-May-2024 to inter-alia consider and approve the Audited Financial results of the Company fo…
Regulatory Filings
2024-05-14 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notice of an upcoming Board Meeting scheduled for 21st May 2024, where the Board will consider and approve the audited financial results for the quarter and financial year ended 31st March 2024. It is addressed to stock exchanges as per regulatory requirements under SEBI Listing Obligations. The document does not contain any financial data or results itself, but is an announcement of a future event (Board Meeting) related to financial results approval. It is not a full Annual Report, Interim Report, or Earnings Release. It is also not a certification or voting result. The document is a formal intimation of a Board Meeting, which fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance notice.
2024-05-14 English
MOREPEN LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2024 ,inter alia, to consider and approve standalone and consolidated ....
Board/Management Information Classification · 95% confidence The document is a notice of an upcoming Board Meeting scheduled to consider and approve the audited financial results for the quarter and financial year ended 31st March 2024. It is addressed to stock exchanges and references compliance with SEBI regulations. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is a formal intimation about the meeting date and agenda, which is typical for a Board/Management Information filing. The document length is short (1641 characters), and it is clearly an announcement rather than a report or detailed filing. Therefore, the appropriate classification is 'MANG' for Board/Management Information.
2024-05-14 English
Please find attached issuance of letter of confirmation against duplicate share certificate
Regulatory Filings
2024-05-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.